Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-264 vs Darzalex in Healthy Volunteers
NCT05974969Phase 1Completed
- Sponsor
- BIOCAD
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bcd-264 in multiple myeloma (MM) (2 arms), sponsored by BIOCAD. Primary endpoint: Area under the serum concentration-time curve from time 0 to infinity. Started May 2023; status: completed.
02
Drugs
bcd-264
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05974969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05974969.